Sage Journals: Discover world-class research

Abstract

Purpose: To investigate outcomes of drug-coated balloon (DCB) angioplasty in endovascular interventions including or restricted to the popliteal artery. Methods: A retrospective analysis was conducted of 266 patients [median age 72 years, interquartile range (IQR) 62, 78; 166 men] treated with DCB angioplasty in 281 de novo lesions including the popliteal artery between December 2011 and January 2015 at a single center. The median lesion length was 270 mm (IQR 150, 373). The study outcomes were primary patency and predictors of restenosis [reported as the hazard ratio (HR) with 95% confidence interval (CI)]. Results: The primary patency was 77.4% at a median 12.2 months (IQR 5.7, 18.8). Independent variables associated with restenosis included baseline Rutherford category (HR 1.36, 95% CI 1.05 to 1.77, p=0.02), reference vessel diameter (HR 0.77, 95% CI 0.63 to 0.95, p=0.02), dissection (HR 1.69, 95% CI 1.022.79, p=0.04), and standard nitinol stent use (HR 2.08, 95% CI 1.14 to 3.79, p=0.02). Conclusion: Outcomes after DCB angioplasty in lesions including the popliteal artery were acceptable compared with previous studies. Further investigation with long-term follow-up is needed to confirm these results.

Keywords

balloon angioplasty dissection drug-coated balloon popliteal artery restenosis stent target lesion revascularization

Get full access to this article

View all access options for this article.

References

Schillinger

Sabeti

Dick

et al . Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.

Laird

Katzen

Scheinert

et al . Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: Three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.

Rastan

Krankenberg

Baumgartner et al . Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery. A prospective, multicenter, randomized trial. Circulation. 2013;127:2535–2541.

Scheinert

Werner

Scheinert

et al . Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2012;5:331–338.

Goltz

Ritter

Kellersmann

et al . Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force. J Endovasc Ther. 2012;19:450–456.

Klein

Chen

Messenger

et al . Quantitative assessment of the conformational change in the femoropopliteal artery with leg movement. Catheter Cardiovasc Interv. 2009;74:787–798.

Scheinert

Sax

et al . Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–315.

Tepe

Zeller

Albrecht

et al . Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.

Werk

Langner

Reinkensmeier

et al . Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.

10.

Werk

Albrecht

Meyer

et al . Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.

11.

Micari

Cioppa

Vadalà

et al . 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease. JACC Cardiovasc Interv. 2013;6:282–289.

12.

Liistro

Grotti

Porto

et al . Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (Drug Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery). JACC Cardiovasc Interv. 2013;6:1295–1302.

13.

Scheinert

Duda

Zeller

et al . The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization. JACC Cardiovasc Interv. 2014;7:10–19.

14.

Tepe

Laird

Schneider

et al ; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.

15.

Rosenfield

Jaff

White

et al . LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.

16.

Schroeder

Werner

Meyer

et al . Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135:2227–2236.

17.

Zeller

Rastan

Macharzina

et al . Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Ther. 2014;21:359–368.

18.

Micari

Nerla

Vadalà

et al . 2-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv. 2017;10:728–734.

19.

Stavroulakis

Schwindt

Torsello

et al . Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017;24:181–188.

20.

Rocha-Singh

Zeller

Jaff

MR.

Peripheral artery calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovascular Interv. 2014;83:212–220.

21.

Huber

Mooney

Madison

et al . Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol. 1991;68:467–471.

22.

Cambiaghi

Spertino

Bertoglio

et al . Fracture of a Supera interwoven nitinol stent after treatment of popliteal artery stenosis. J Endovasc Ther. 2017;24:447–449.

23.

Rastan

McKinsey

Garcia

et al . One-year outcomes following directional atherectomy of popliteal artery lesions: subgroup analysis of the prospective, multicenter DEFINITIVE LE Trial. J Endovasc Ther. 2018;25:100–108.

24.

Tepe

Zeller

Schnorr

et al . High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.

25.

Rosenfield

Schainfeld

Pieczek

et al . Restenosis of endovascular stents from stent compression. J Am Coll Cardiol. 1997;29:328–338.

26.

Zhao

Nikanorov

Virmani

et al . Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009;32:720–726.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

2.15 MB

Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement

Abstract

Keywords

Get full access to this article

References

Supplementary Material